Depomed (DEPO): Positive News Flow But There Is Risk If The Company Manages The Sale - RBC

September 21, 2016 8:44 AM EDT
Get Alerts DEPO Hot Sheet
Price: $18.25 -1.35%

Rating Summary:
    10 Buy, 4 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 18 | Down: 17 | New: 10
Trade DEPO Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

RBC Capital analyst, Randall Stanicky, reiterated his Sector Perform rating on shares of DepoMed Inc (NASDAQ: DEPO) noting that news flow is about to pick up meaningfully following (i) last week's press report that DEPO may be preparing to put itself up for sale (ii) the 9/19 Starboard letter underscoring its position ahead of the recently set 11/15 shareholder vote and (iii) NUCYNTA legal decision expected by next Fri.

The NUCYNTA decision is expected from Judge Cecchi by Sept 30 (next Fri) and seems likely to add to the company's value. The analyst is most focused on the '364 patent (Dec 2025), which covers both the IR/ER versions (i.e., all NUCYNTA) and is the more debated of the three patents. The analyst believes that absent big surprises any move on a decision is likely worth ~$1.50 to $2.00.

It's unclear if DEPO will have a response to Starboard but the analyst thinks there is risk in the company running a formal sale process. No change to the price target of $22.

For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.

Shares of DepoMed Inc closed at $24.22 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

RBC Capital

Add Your Comment